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Patients affected by pseudohypoparathyroidism (PHP) or related disorders are characterized by 
physical findings that may include brachydactyly, short stature, a stocky build, early-onset 
obesity, ectopic ossifications, neurodevelopmental deficits, as well as hormonal resistance most 
prominently to parathyroid hormone (PTH). In addition to these alterations, patients may 
develop other hormonal resistances, leading to overt or subclinical hypothyroidism, 
hypogonadism and growth hormone (GH) deficiency, impaired growth without measurable 
evidence for hormonal abnormalities, type 2 diabetes and skeletal issues with potentially severe 
limitation of mobility. 
PHP and related disorders are primarily clinical diagnoses. Given the variability of the clinical, 
radiological and biochemical presentation, establishment of the molecular diagnosis is of critical 
importance for patients. It facilitates management, including prevention of complications, 
screening and treatment of endocrine deficits, supportive measures, and appropriate genetic 
counselling.  
Based on the first international consensus statement for these disorders, this article provides an 
updated and ready-to-use tool to help physicians and patients outlining relevant interventions 
and their timing. 
A life-long coordinated and multidisciplinary approach is recommended, starting as far as 
possible in early infancy, and continuing throughout adulthood with an appropriate and timely 
transition from paediatric to adult care.  
Keywords: Acrodysostosis, Bone disorders, Brachydactyly, Calcium and Phosphate metabolism, 
Consensus, Diagnosis, Management, Ossification, Parathyroid hormone, 
Pseudohypoparathyroidism, Treatment  
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Introduction 
Much progress has been made since 1942 when Albright and colleagues described 
pseudohypoparathyroidism (PHP) as a novel disorder of hormone resistance, in which 
hypocalcaemia and hyperphosphataemia were due to decreased responsiveness to parathyroid 
hormone (PTH). Patients also manifested an unusual appearance characterized by short stature, 
brachydactyly, obesity with a round face, and heterotopic ossifications. This was known as 
Albright hereditary osteodystrophy (AHO)[1]. Initially, reports focused on clinical aspects, 
leading to the identification of a constellation of disorders associated with a similar spectrum of 
physical characteristics, neurocognitive and endocrine abnormalities, which included the 
different subtypes of PHP (i.e., PHP1A, PHP1B, PPHP, POH).  
Today the term pseudohypoparathyroidism (OMIM #103580 for PHP type 1A (PHP1A), #603233 
for PHP type 1B (PHP1B) and #612462 for PHP type 1C (PHP1C)) describes disorders that share 
biochemical characteristics of hypoparathyroidism, i.e. hypocalcaemia and 
hyperphosphataemia, as a result of proximal tubular resistance to PTH. Some patients present 
with resistance to other hormones (such as thyroid-stimulating hormone (TSH), and/or 
gonadotropins, growth-hormone-releasing hormone and calcitonin).  
Patients with PHP1A, and rare PHP1B cases, manifest physical features of AHO due to defects in 
chondrocyte and osteoblast differentiation, early closure of growth plates, brachydactyly, short 
stature and development of ectopic ossifications. AHO typically develops during late childhood. 
Years after the description of PHP, Albright and coworkers described patients with some physical 
features of AHO despite appropriate PTH responsiveness. Albright originally termed this 
condition pseudopseudohypoparathyroidism (PPHP; OMIM #612463). We know today that 
progressive osseous heteroplasia (POH; OMIM #166350) or osteoma cutis belong to the same 
disease entity, with variable extent of the heterotopic ossifications and brachydactyly. On the 
other side, PTH resistance in absence of AHO phenotype is the main characteristic of most 
PHP1B patients[2]. Recent studies have further defined the phenotype of these related disorders 
including other associated features such as impaired intrauterine growth in PPHP[3], and early-
onset obesity[4], frequent respiratory and ENT complications [5], delayed verbal[6] and non-
verbal[7] milestones and cognitive impairment[7], mainly in PHP1A.  
 
Since the 1990s, PHP1A and PPHP are known to be caused by heterozygous Gsα inactivating 
pathogenic variants[8,9]. It was subsequently shown that the disease phenotype associated to 
the variant depends on the alterations’ maternal (PHP1A) or paternal (PPHP)[10] / POH[11] 
inheritance. The molecular mechanism leading to PHP1B was discovered in 2003. Patients 
affected with PHP1B present with methylation defects at the GNAS locus[12] (see “Molecular 
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diagnosis” section below). The term of PHP type 1C was initially used for patients displaying a 
PHP1A phenotype yet a biochemical normal Gsα activity; as for now, the denomination should 
now be abandoned and patients referred to as PHP1A, as they carry maternally inherited 
inactivating pathogenic Gsα variants.  
New biochemical and molecular techniques have uncovered that disorders similar to PHP, such 
as acrodysostosis (OMIM #101800)[13,14], are due to different defects within various genes 
involved in the stimulatory G-protein-coupled receptor signaling pathway[15] (e.g. 
GNAS[2,16,17], PRKAR1A[14], PDE4D[13,18] or PDE3A[19]). Today, molecular analyses can 
identify de novo or inherited genetic or epigenetic alterations in around 80-90% of patients with 
PHP or related disorders[20,21] (Figure 1). 
 
Since publication of the original Consensus Statement for PHP and related disorders[22], new 
relevant findings have been published. Therefore, with the aim of disseminating and updating 
the international consensus statement, the three main investigators (AL, GM and GPdN) 
together with 34 of the 37 experts collaborated on this shortened and updated paper. 
Literature search was updated from December 18th, 2016 to 31st December, 2019 using the same 
key terms as in the previous version, leading to a total of over 1000 articles. 
The addition of the recently published evidence did not modify the content of the previously 
published recommendations but further strengthened the underlying background and experts’ 
opinions and prompted us to develop a more concise and practical tool designed to help health 
care professionals involved in the management of patients with PHP and patients and their 
families. 
 
Clinical diagnosis and management 
PHP and the afore-mentioned disorders share a common defect in the cAMP signaling pathway 
downstream of the PTH/PTHrP receptor. Despite this unifying molecular umbrella, presentation 
and disease severity can vary considerably between affected individuals, even amongst patients 
carrying the same genetic alteration, highlighting the important clinical and molecular overlap 
of these diseases. Newborns and young infants usually present with unspecific features such as 
being born small for gestational age (SGA)[23], early onset obesity[3] or transient 
hypothyroidism. In the absence of familial history or typical symptoms such as ectopic 
ossifications, diagnosis may be delayed for years due to lack of recognition of the syndrome and 
associated features. Later in life, growth failure, brachydactyly, obesity, and/or hypocalcaemia 
leading to neuromuscular symptoms or even seizures often lead to investigations and 
identification of the underlying cause.  
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Therefore, diagnosis of PHP and related disorders should be based on clinical and biochemical 
characteristics, and, in some cases, family history.  
The following major features should be present in order to diagnose a patient with PHP or 
related disorder: PTH resistance and/or ectopic ossifications, and/or early-onset (before 2 years 
of age) obesity associated with TSH resistance, and/or AHO. In addition, other features can be 
considered as supporting the diagnosis of PHP and related disorders: unexplained primary 
hypothyroidism, hypercalcitoninaemia, hypogonadism, growth hormone deficiency, cognitive 
impairment, hearing impairment, craniosynostosis and neurosurgical features, tooth ankylosis, 
oligodontia, cataract and/or CNS calcifications, sleep apnoea, ear infections, asthma, and 
restricted fetal growth (Figure 2).  
Once a clinical suspicion exists, molecular analyses are critically important for genetic 
counselling and in some cases for diagnosis, particularly when there is significant overlap in 
clinical features (e.g. PHP1A versus acrodysostosis). Nowadays, the genetic or epigenetic 
diagnosis relies on the most likely identified causes of the disease at the time of analysis 
according to the algorithm (Figure 3). The use of genetic and epigenetic analyses to diagnose 
patients with PHP and related disorders has reduced the need for administration of exogenous 
PTH or assessment of Gsα bioactivity. 
Altogether, a correct diagnosis will guide appropriate management including prevention of 
complications, lifestyle adjustments, screening and treatment of endocrine deficits and 
appropriate genetic counselling.  
 
Sufficient prospective clinical trials and outcomes data in PHP and related disorders is lacking. 
Thus, management guidelines are mainly based on experts’ consensus. We have summarized in 
this document (see below) and in table 1, the principal multi-disciplinary interventions that 
should take place during the follow-up of these patients. 
 
Resistance to PTH 
 
PTH resistance is the hallmark of PHP, found in 45-80%[24] of the patients, particularly in those 
with PHP1A and 1B. It is defined as by the association of hypocalcaemia, hyperphosphataemia 
and elevated serum levels of PTH in the absence of vitamin D deficiency, abnormal magnesium 
levels and/or renal insufficiency[22]. PTH resistance is usually absent at birth and develops over 
time[25]; in addition, the diagnosis maybe difficult in the absence of one or several biochemical 
features, e.g. hypocalcaemia; or hyperphosphataemia[13,18,22,26–28]. Typically, in children, 
symptoms appear during periods of rapid growth, most likely because of increased calcium and 
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vitamin D requirements[29]. The screening and follow-up of PTH resistance should include 
measurement of PTH, 25-OH-vitamin D, calcium and phosphate every 3 to 6 months in children 
and at least yearly in adults. Monitoring should be more frequent in symptomatic individuals 
and during acute phases of growth, intercurrent illness, pregnancy and breastfeeding, when 
dosage requirements for active vitamin D metabolites or analogues might change. Patients 
and/or their family should be taught to recognize clinical  signs of hypocalcaemia and 
hypercalcaemia[22].  
Management of severe symptomatic hypocalcaemia does not differ from that of 
hypoparathyroidism[30]. However, treatment using activated forms of vitamin D combined with 
(in most cases) oral calcium supplementation should target levels of calcium and phosphorus 
within the normal range, whilst avoiding hypercalciuria; PTH levels should be within mid-normal 
to up to two-times the upper limit of normal as higher levels of PTH might have adverse effects 
on skeletal mineralization or on the growth plate and evolve towards tertiary 
hyperparathyroidism[31–34]. Whatever the level of serum calcium, treatment with active 
vitamin D analogues should be considered when PTH levels reach more than twice the upper 
level of normal. Calcium supplements should also be considered, depending on the calcium 
dietary intake. Normal levels of 25-OH-vitamin D should be maintained  for all patients with 
appropriate supplementation[22]. 
 
Patients with PHP and related disorders rarely develop hypercalciuria and/or nephrocalcinosis 
because of the preserved PTH sensitivity of the distal renal convoluted tubules[29,35,36]. 
However, episodes of nephrolithiasis have been seldomly observed (unpublished observations) 
in patients with PHP1A and PHP1B, particularly after completion of pubertal growth. Monitoring 
of urine calcium levels is recommended at regular intervals during treatment, as well as 
appropriate renal imaging in patients with persistent hypercalciuria on repeated 
measurements[22,30]. 
Chronic hypocalcaemia with hyperphosphataemia can result in an elevated calcium x phosphate 
product, which can lead to ectopic calcification (not to be confused with the ectopic ossification 
of AHO that occurs independently of serum levels of calcium and phosphate). Intracranial 
calcifications of the basal ganglia resemble those occurring in Fahr syndrome due to pathogenic 
variants in the SLC20A2 gene; note that patients with PHP may often have additional calcification 
of the cerebral white matter[37]. So far, brain calcifications have not been described in patients 
with PPHP, POH or those with an alteration in the PRKAR1A or PDE4D genes[13,14,38–41]. 
Ectopic depositions of calcium and phosphorus may occur in the eyes, leading to posterior 
subcapsular cataract or corneal opacities[41–45]. Brain CT scan is indicated only in the case of 
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neurological manifestations, whilst systematic and regular ophthalmologic examination is 
recommended to diagnose or manage cataracts. 
Finally, pseudohypoparathyroidism is often associated with dental and oral features such as 
failure of tooth eruption, impaction of primary molars, hypodontia, enamel hypoplasia, 
malocclusion, gingival hyperplasia, gingivitis with spontaneous bleeding and pain[46–49]. 
Regular 6-12 monthly dental reviews are recommended, at least during childhood[22,50]. 
 
Ectopic ossification 
Ectopic ossifications are found in 100% and 80–100% of patients with POH and PPHP/AHO 
respectively, in 30–70% of PHP1A patients, and very sporadically in those with PHP1B, while they 
have never been reported in patients with acrodysostosis[27,51]. Ectopic ossifications should be 
therefore considered as a specific consequence of GNAS molecular alterations, especially when 
located on the paternal allele[52]; Gsα deficiency in mesenchymal stem cells favors de novo 
formation of extra-skeletal islands of ectopic bone in dermis and subcutaneous fat[53,54]. 
 
In contrast to what has been described in Gnas knockout mouse models of AHO[55], and unlike 
fibrodysplasia ossificans progressiva (FOP), there is no scientific evidence that inflammation or 
traumatic events contribute to ectopic bone formation in GNAS-related conditions[56,57]. 
Notwithstanding, ectopic bone formation often develops, in GNAS related disorders, in locations 
subjected to high pressure loads, such as the heel[58]. 
POH is defined by ossifications located in and extending towards connective tissues, muscles, 
tendons and ligaments[11,52,57]. In contrast, ectopic bone formation remains superficial in 
osteoma cutis, PHP1A, PPHP or AHO. 
Ectopic ossifications are uncommon in the general population, and the presence of these lesions 
should trigger a clinical and biochemical work up to search for signs of AHO, PTH and TSH 
resistance, or FOP. Skin biopsy is not necessary in obvious cases and contraindicated in case of 
suspicion of FOP.  
 
Due to the rarity of these conditions, limited information is available about prognosis, and so far 
no effective treatments exist for the management or prevention of ectopic ossifications.  
Cutaneous bony plaques should be investigated by careful clinical examination at each visit, 
especially in patients with pathogenic or probably pathogenic variants on the GNAS paternal 
allele (POH and PPHP). Patients and families should be instructed about self-examination. 
Location and size of the ossifications, involvement of joints and impairment of movement and 
bone growth, and evolution during puberty or rapid growth should be documented at each visit.  
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Imaging of ossifications should be performed using CT or MRI only in the case of painful or 
symptomatic lesions, if joint or organ function is being jeopardized, or when considering surgical 
excision. 
Physical therapy and meticulous skin care are critical for the prevention of complications due to 
ectopic ossifications. Due to a high risk of recurrence, surgical excision should be limited to well-
delimitated, superficial lesions causing pain and/or movement impairment [11,22,57]. In 
ossifications involving joints, immobilization, e.g. through casts, should be avoided to prevent 
ankyloses. No evidence supports the use of non-steroidal anti-inflammatory drugs, 




Brachydactyly is not specific to PHP and related disorders. Affected patients display 
brachydactyly type E[59], with a high degree of variability in frequency and severity. 
Brachydactyly is found in the majority of patients with PHP1A and PPHP (70-80%), in few with 
PHP1B (15-33%), and in all patients with acrodysostosis[22] (Figure 2).  
Brachydactyly develops over time and might not be present or visible in early life, except in 
patients with acrodysostosis[14,60]. The clinical and radiological examination of the hands and 
feet is important from early childhood onwards to establish the diagnosis. It may impair fine 
motor skills, such as handwriting[61]. In some patients occupational therapy and/or appropriate 
orthopedic devices may be indicated, e.g. special shoes and orthopedic insoles[22]. 
 
Additional bone features have been described such as carpal tunnel syndrome[61], Madelung 
deformity[62], spinal stenosis[63], acro-osteolysis, phalangeal cone-shaped epiphyses, and 
craniosynostosis[64]. Depending on the functional consequences, these skeletal manifestations 
may require a specific multidisciplinary evaluation and orthopedic corrective surgery[22]. 
 
Management of growth and GH deficiency  
The majority of PHP1A and PPHP patients display adult short stature, 2.5 SD below mean in 
average, despite having normal length/height during childhood[3]. Short stature is even more 
pronounced in acrodysostosis, with final height being on average -3.5 SD (-8.8 to -0.5 SD)[22]. 
Noticeably, most patients with a paternal GNAS pathogenic variant mutation (that is, patients 
with PPHP or POH) and patients with acrodysostosis show a restricted foetal growth and are 
thus born small for gestational age (SGA)[22]. Intrauterine growth restriction, advanced bone 
maturation, impaired pubertal growth spurt, and, in PHP1A, growth hormone-releasing 
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hormone (GHRH) resistance and consequently GH deficiency, can contribute to the premature 
cessation of growth and short stature in adulthood[3,22]. Careful and regular monitoring of 
growth, skeletal maturation and GH secretion is therefore advised in all affected children, 
starting around the age of 3-6 years. Patients born SGA who do not demonstrate appropriate 
catch-up growth or patients showing GH deficiency should be rapidly considered for treatment 
with rhGH[22]. As of today, there is insufficient evidence to establish efficacy and safety of 
pubertal blockers to increase final height in these patients[65]. In contrast to PHP1A and PPHP 
patients, and despite an enhanced growth velocity during infancy, PHP1B patients display adult 
heights similar to that of the general population[3,66].  
 
Obesity 
Patients with PHP1A or PHP1B develop early-onset obesity, usually within the first 2 years of 
life; this may be the first and only symptom in many patients until diagnosis is established during 
adolescence or adulthood[3,4,67,68]. Several mechanisms may contribute to excessive 
acquisition and maintenance of fat mass, including a defect in the Gsα-dependent melanocortin 
signaling pathway (possibly responsible for the patients’ hyperphagic trait[68,69]), decreased 
resting energy expenditure compared with obese controls[70,68,71], low sympathetic nervous 
system activity, decreased lipolysis[72], and growth hormone-releasing hormone resistance in 
the pituitary[73,74]. Overall, we now know that obesity or overweight are associated with all 
types of PHP and related disorders[22] with the exception of POH, PPHP and osteoma 
cutis[3,52,57,75,76]. Once diagnosis is made, BMI and eating behavior should be regularly 
monitored. Patients, parents and families should be provided with psychological support and 
educational programs, as early as possible, even in the presence of a normal BMI as a preventive 
strategy, also taking into account the low resting energy expenditure of these patients[3]. 
 
Sleep apnea, well-known complication of obesity, is reported to be more frequent in patients 
affected with PHP1A[77,78], and may also be present in acrodysostosis[40]. Phenotypically, 
these patients present with round faces, a flattened nasal bridge and/or maxillary 
hypoplasia[26,50] which combined with obesity mechanically contributes to the development 
of sleep and respiratory disturbances[70,77]. All patients with PHP and related disorders should 
therefore be screened for restless sleep, snoring, inattentiveness and daytime somnolence and, 




Decreased insulin sensitivity and type 2 diabetes are present in a large proportion of adult 
PHP1A patients and may not be solely related to obesity[79]. Post-prandial hyperglycemia is 
common in children with PHP1A and PHP1B [71]. Lipid profile is not profoundly affected in 
PHP1A patients[69,80]. Hypertension was reported in one study of PHP[81] yet the incidence of 
cardiovascular diseases is not increased in cohort studies conducted in Denmark[41,80]. Other 
studies have failed to find an increased risk of hypertension compared to matched controls 
[69,71,79]. Overall, we propose to include regular monitoring of blood pressure, lipid profile and 
glucose metabolism parameters within the regular multidisciplinary follow-up of patients 
affected with PHP and related disorders.  
 
Cognitive features 
Cognitive impairment has been reported in 40-70% of patients with PHP1A, in 0-10% of patients 
with PPHP or POH, is rarely observed in patients with PHP1B and has a variable prevalence in 
patients with acrodysostosis[22]. Cognitive performance studies have been undertaken only in 
PHP1A and showed reduced scores in comparison to peers[6,37,82,83], with an average IQ of 
85.9 and a reduction of 21.5 IQ points below an unaffected sibling[7]. Patients with PHP1A were 
found to have impaired executive function, delayed adaptive behavior skills and increased rates 
of attention deficit hyperactivity disorder (ADHD)[7]. One retrospective review of 
developmental milestones showed a greater delay in language compared with gross motor skills, 
with and a tendency to improve during late childhood[6]. Neurological and neuropsychiatric 
manifestations can be linked to the function In addition to the role of Gsα in brain 
development[84], and other organic CNS alterations, including Chiari 1 malformation[85–87] or 
prolonged periods of hypocalcaemia[83,87] found in some patients. Patients with PHP and 
related disorders should be referred to a neuropsychologist for neurocognitive and/or 
behavioral assessment at diagnosis or at pre-school age, especially in patients with PHP1A and 
acrodysostosis due to PDE4D pathogenic variants mutations. Most patients will require 
specialized educational assistance[7]. 
 
TSH resistance 
TSH resistance is not as severe as PTH resistance due to partial Gsα imprinting in the thyroid 
tissue[88–90]. Most patients with PHP1A[51,74] present elevated serum levels of TSH, a small 
thyroid gland and normal or only mildly depressed serum levels of thyroid hormone. Elevated 
levels of TSH due to TSH resistance are often present at birth; some patients may be diagnosed 
through the neonatal screening[22]. In contrast, PHP1B patients display TSH levels at the upper 
end of normal or mildly elevated[22]. TSH resistance is present in patients with acrodysostosis 
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due to pathogenic variants at PRKAR1A but not in those at PDE4D[26,27]. Despite a prompt 
diagnosis of hypothyroidism after birth and initiation of treatment, this does not seem to 
prevent motor or cognitive delay[82].  
In children and adults, investigation, monitoring and treatment objectives do not differ from 
other aetiologies of hypothyroidism/subclinical hypothyroidism, including hypothyroidism 
related to TSH resistance[22,91]. 
 
Alterations in gonadal function  
Gonadal function and puberty 
Resistance to gonadotrophins is more subtle than resistance to other hormones such as PTH and 
TSH. This suggests that PHP1A patients display only partial resistance to gonadotropins[22,92]. 
Clinically, patients may present with menstrual irregularities in girls[92], cryptorchidism in boys 
([93] and experts’ experience), and blunted or absent pubertal growth spurt in adolescents[3] 
with PHP1A. PHP1B and PPHP patients seem to have normal gonadal function[94], while variable 
resistance to gonadotropins has been described in patients with acrodysostosis and pathogenic 
variants in the PRKAR1A gene[26].  
In children with PHP or related disorders, Tanner staging of sexual maturation and testicular 
descent and location should be regularly assessed. As skeletal maturation is typically advanced 
in these children, bone age should be radiographically determined. Conversely, biochemical 
assessment of gonadal status is not recommended unless clinically indicated. Cryptorchidism 
and/or hypogonadism, when present, should be corrected and managed according to standard 
recommendations[22]. 
 
Fertility and pregnancy 
Assisted and spontaneous pregnancies have been reported in women with PHP and related 
disorders[22,92,95]. Men with PHP1A have also fathered children. For disease transmission 
risks, see “Molecular diagnosis” section. 
In case of hypocalcaemia and/or hypothyroidism, pregnant women with PHP and related 
disorders should be monitored following the international guidelines for any pregnancy 
associated with these disturbances. Vaginal delivery may be contra-indicated due to reduced 
pelvic size and decreased range of motion of the hips due to local ossifications[22]. The newborn 
should be evaluated for the presence of skin ossifications, levels of TSH, calcium and 
phosphorus. Breastfeeding is not contraindicated, but close follow-up and clinical monitoring of 
the baby is advised[22]. 
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Menopause and osteoporosis 
Although patients with PHP do have several potential risk factors for bone fragility, they do not 
generally demonstrate evidence for decreased bone density and/or increased fracture 
risk[41,96,97]; in this context, routine DXA measurements is not indicated[22]. On the other 
hand, further investigation is required should a diagnosis of osteoporosis be suspected, for 
instance after sustaining a low trauma fracture, or in the case of skeleton unloading (e.g. joint 
ankyloses secondary to aberrant ossification). Patients should then be screened for potential 
secondary causes of bone loss such as vitamin D deficiency, hypogonadism or growth hormone 
deficiency, and all efforts should be made to correct these before treating the osteoporosis if 
still required according to national and international standard recommendations. 
 
Other hormone resistances 
Elevated calcitonin levels, most likely due to calcitonin resistance, have been reported in 
PHP1A[98,99], PHP1B and acrodysostosis patients with PRKAR1A pathogenic variants[14]. They 
may be used to support the diagnosis of PHP and related disorders. Additional resistance to 
hormones that mediate their actions through Gsα-coupled receptors have also been previously 
reported, although, the clinical relevance of these abnormalities remains to be established[100]. 
Screening of additional hormone resistances, and calcitonin measurement, is not recommended 
in patients with PHP and related disorders, except for diagnostic purposes[22].  
 
Molecular diagnosis 
The main subtypes of PHP and related disorders are caused by de novo or autosomal dominant 
inherited inactivating genetic pathogenic variants within the genes of the PTH/PTHrP signalling 
pathway[15] or by epigenetic alterations at GNAS locus. GNAS locus presents four distinct 
differentially methylated regions (DMRs) (see supplementary figure 1): the paternally 
methylated GNAS-NESP:TSS-DMR and three maternally methylated GNAS-AS1:TSS-DMR, GNAS-
XL:Ex1-DMR and GNAS A/B:TSS-DMR. 
 
PHP1A is caused by inactivating pathogenic variants on the maternal allele of the GNAS gene, 
including both single nucleotide and copy number variants [8,9,22]. When the pathogenic 
variants are on the paternal allele, the outcome is mainly PPHP, but can also include osteoma 
cutis or POH[11,22]. Single nucleotide variants can be easily detected by sequence analysis 
whereas genomic rearrangements can be detected by quantitative methods[101]. 
Determination of the affected allele in de novo cases is becoming relevant, as a few PPHP 
patients may also develop hormone resistance[102]. Genetic counselling is critical for PHP and 
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related disorders; patients with GNAS genetic variants have a 50% chance of transmitting the 
molecular defect. Depending on parental sex, their offspring will develop PPHP, osteoma cutis, 
or POH (when the transmitting patient is male) or PHP1A (when the transmitting patient is 
female). 
 
Loss of methylation at GNAS A/B:TSS-DMR is detected in all patients with PHP1B[22,103]. When 
it is the only affected DMR (15–20% of PHP1B cases)[21], it is most often the consequence of an 
alteration in the maternal allele of cis-acting control elements within STX16[12]. Other 
maternally inherited deletions and duplications have also been identified in some rare familial 
cases, affecting either an isolated GNAS A/B:TSS-DMR or all four DMRs[22]. This clinical form is 
classified as AD-PHP1B, due to its autosomal dominant mode of inheritance when maternally 
inherited (i.e., paternally inherited deletions are not associated with methylation defects)[12]. 
 
On the other hand, sporadic PHP1B is often associated with methylation defects at two or more 
DMRs, in addition to GNAS A/B:TSS-DMR, with no identified underlying genetic 
mechanism[104]. In around 8-10%[21,105] of these sporadic cases, the methylation anomalies 
are caused by paternal uniparental disomy of the chromosomal region comprising GNAS 
(UPD(20q)pat)[22,106]. In these patients, recurrence and transmission risks are expected to be 
similar to that of the general population. 
 
Although GNAS methylation defects can be detected through the use of several methods, a 
methylation sensitive-MLPA (MS-MLPA) kit from MRC-Holland (MS-MLPA ME031 GNAS) enables 
the detection simultaneously of methylation defects at the different GNAS-DMRs as well as 
STX16 and NESP/AS deletions and deletions encompassing GNAS[107]. 
Paternal uniparental isodisomy can be analyzed either by microsatellite (STR) typing or SNP 
array.  
 
In brief, in individuals with a suspected diagnosis of PHP, molecular diagnosis must include DNA 
sequence, methylation and CNVs analyses at the GNAS locus following the proposed algorithm 
described in Figure 3. 
 
Acrodysostosis can be caused by heterozygous point pathogenic variants in PRKAR1A or 
PDE4D[13,14,18], so they can be easily detected by sequencing. They mostly occur de novo[22], 
so the recurrence risk is similar to that of the general population. As it presents an autosomal 
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dominant way of inheritance, patients have a 50% of chance of passing on the molecular defect 
and the disease to their children. 
 
Conclusions 
Patients with PHP and related disorders may display a highly heterogeneous and progressive 
clinical picture over their life span from infancy to adulthood, which renders a life-long 
multidisciplinary approach mandatory. Each of the many clinical aspects and potential 
complications of the disease should be managed by health care professionals with expertise in 
these disorders, preferably when possible at referral centers. In addition, the different and 
complex genetic and epigenetic defects underlying these disorders also require a specialized 
approach in order to establish a correct molecular diagnosis, which is often difficult and time-
consuming for both patients and their families, but that might in turn help clinicians to look for 
specific clinical manifestations with consequent appropriate management.  
Following up on the recent publication of the first international consensus statement on these 
disorders, this article provides an updated concise and ready-to-use tool for physicians and 
patients with Table 1 summarizing the main interventions as well as their timing. 
Given the lack of strong evidence-based data, particularly for the management of these patients, 
there is an urgent need to implement registries with large cohorts of patients, to better 
understand the natural history of PHP and related disorders, to identify the intersections as well 
as the specificities of these clinically heterogeneous but closely related diseases and, last but 
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Figure 1: Molecular defects in the PTH–PTHrP signalling pathway in PHP and related disorders. 
The main clinical features of PHP and related disorders are due to molecular defects within the 
PTH–PTHrP signalling pathway, with the exception, perhaps, of ectopic ossification. Some of the 
clinical features result from the impaired signaling of other GPCRs such as TSHR. The diseases 
caused by alterations at the genes codifying the indicated proteins are shown in bold. 
Differential diagnoses are indicated in grey. PTHR1: PTH/PTHrP receptor type 1; G protein: 
trimer a, b, g; cAMP: grey diamond; PKA: tetramer R (regulatory subunit 1A; dense grey) and C 
(catalytic subunit; light grey); phosphodiesterases: ovals PDE4D and PDE3A; PHP: 
pseudohypoparathyroidism; HTNB: autosomal dominant hypertension and brachydactyly type 
















Figure 2: Main clinical features of PHP and related disorders. PHP and related disorders affect 
many organs unequally. The clinical and biochemical features of the main diseases have been 
represented with their frequency when known. PHP1A: pseudohypoparathyroidism type 1A due 
to maternal loss of function variants at the GNAS coding sequence, PHP1B: 
pseudohypoparathyroidism type 1B due to methylation defect at GNAS locus; PPHP: 
pseudopseudohypoparathyroidism due to paternal loss of function genetic variant at the GNAS 
coding sequence; POH: progressive osseous heteroplasia due to paternal loss of function variant 
at the GNAS coding sequence; ACRDYS1: acrodysostosis due to pathogenic variant in PRKAR1A; 














Figure 3: Molecular algorithm for the confirmation of the diagnosis of PHP and related 
disorders. If patients present with Albright’s hereditary osteodystrophy (AHO), genetic 
alterations at GNAS should be studied, including point variants (sequencing) and genomic 
rearrangements (such as MLPA and aCGH). In the absence of AHO, epigenetic alterations should 
be analyzed first. According to the results obtained for the methylation status, further tests are 
needed to reach the final diagnosis: if the methylation defect is restricted to GNAS A/B:TSS DMR, 
STX16 deletions should be screened for, and, if present, the diagnosis of AD-PHP1B is confirmed; 
if the methylation is modified at the four DMRs, paternal uniparental disomy of chromosome 20 
[UPD(20q)pat] should be screened for; in absence of UPD(20q)pat, deletions at NESP should be 
screened for; if no genetic cause is identified as the cause of the methylation defect, the sporadic 
form of the disease (spor-PHP1B) is suspected. After exclusion of the GNAS locus as the cause of 
the phenotype, and in patients with AHO, PHP-related genes (that is, at least PDE4D and 
PRKAR1A) should be sequenced. RT-PCR: Reverse-Transcription Polymerase Chain Reaction; 
SNP: Single Nucleotide Polymorphism; NGS: Next-Generation Sequencing; A/B: GNAS A/B: TSS-
DMR; STRs: Short Tandem Repeats (microsatellites); UPD: uniparental disomy; WES: Whole 
Exome Sequencing; WGS: Whole Genome Sequencing; ICR: imprinting control region; VUS: 











Sup Figure 1: Scheme of the GNAS locus. Schematic diagram of the human GNAS cluster with 
DMRs (lollipops indicate the methylation pattern: in red maternally imprinted and in blue, 
paternally ones). The arrows show initiation and direction of transcription for maternal (mat)- 
and paternal (pat)-derived transcripts (in red and blue, respectively). Each box or vertical line 
represent each exon (empty boxes, when exons give rise to noncoding RNAs). GNAS exon 1 
(1Gsα) is outlined in red to indicate that GNAS is preferentially expressed from maternal allele 
in some tissues (proximal renal tubules, neonatal brown adipose tissue, thyroid, gonads, 
paraventricular nucleus of the hypothalamus and pituitary). Discontinue lines represent the 
alternative splicing of each isoforms derived from GNAS cluster (the alternative splicing of 2-13 
exons of GNAS gene were omitted).  
 
